Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Jobst Vascular Center
mi
from
Toledo, OH
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Jobst Vascular Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Oklahoma Foundation for Cardiovascular Research
mi
from
Oklahoma City, OK
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Oklahoma Foundation for Cardiovascular Research
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Lancaster General Hospital
mi
from
Lancaster, PA
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Lancaster General Hospital
mi
from
Lancaster, PA
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Temple University Health System
mi
from
Philadelphia, PA
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Temple University Health System
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Allegheny General Hospital
mi
from
Pittsburgh, PA
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Allegheny General Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Sanford Clinical Research
mi
from
Sioux Falls, SD
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Sanford Clinical Research
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Clinical Research Solutions, P.C.
mi
from
Knoxville, TN
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Clinical Research Solutions, P.C.
mi
from
Knoxville, TN
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Saint Thomas Research Institute, LLC
mi
from
Nashville, TN
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Saint Thomas Research Institute, LLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
The Methodist Hospital Research Institute
mi
from
Houston, TX
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
The Methodist Hospital Research Institute
mi
from
Houston, TX
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Scott and White Memoral Hospital
mi
from
Temple, TX
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Scott and White Memoral Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Virginia Commonwealth University
mi
from
Richmond, VA
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Swedish Medical Center
mi
from
Seattle, WA
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Medizinische Hochschule Hannover
mi
from
Hannover,
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Medizinische Hochschule Hannover
mi
from
Hannover,
Click here to add this to my saved trials
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Open-label Extension Study to CQTI571A2102 to Evaluate the Long-term Safety, Tolerability and Efficacy of QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  7/13/2015
Novartis Investigative Site
mi
from
Mineola, NY
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Open-label Extension Study to CQTI571A2102 to Evaluate the Long-term Safety, Tolerability and Efficacy of QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 7/13/2015
Novartis Investigative Site
mi
from
Mineola, NY
Click here to add this to my saved trials
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Open-label Extension Study to CQTI571A2102 to Evaluate the Long-term Safety, Tolerability and Efficacy of QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  7/13/2015
Novartis Investigative Site
mi
from
Darlinghurst,
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Open-label Extension Study to CQTI571A2102 to Evaluate the Long-term Safety, Tolerability and Efficacy of QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 7/13/2015
Novartis Investigative Site
mi
from
Darlinghurst,
Click here to add this to my saved trials
Global DuoTrav® Study
Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker
Status: Enrolling
Updated:  7/13/2015
Contact Alcon Call Center for Trial Locations
mi
from
Fort Worth, TX
Global DuoTrav® Study
Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker
Status: Enrolling
Updated: 7/13/2015
Contact Alcon Call Center for Trial Locations
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
Status: Enrolling
Updated:  7/22/2015
Clinical Research Facility
mi
from
Newport Beach, CA
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
Status: Enrolling
Updated: 7/22/2015
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
FFA Hypertension and Inflammation in Lean and Obese Subjects
Free Fatty Acids-Induced Hypertension, Endothelial Dysfunction, Inflammation, Insulin Resistance, and Autonomic Dysfunction in Lean and Obese Subjects
Status: Enrolling
Updated:  7/23/2015
Grady Memorial Hospital
mi
from
Atlanta, GA
FFA Hypertension and Inflammation in Lean and Obese Subjects
Free Fatty Acids-Induced Hypertension, Endothelial Dysfunction, Inflammation, Insulin Resistance, and Autonomic Dysfunction in Lean and Obese Subjects
Status: Enrolling
Updated: 7/23/2015
Grady Memorial Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigator Site
mi
from
Birmingham, AL
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
Phoenix, AZ
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative site
mi
from
Los Angeles, CA
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
San Francisco, CA
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
Weston, FL
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
Weston, FL
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigator Site
mi
from
Chicago, IL
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigator Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
Rochester, MN
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
St. Louis, MO
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
Omaha, NE
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
Mineola, NY
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
Mineola, NY
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis
mi
from
New York, NY
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis
mi
from
New York, NY
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
Durham, NC
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
Durham, NC
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
Cincinnati, OH
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
Cleveland, OH
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
Cleveland, OH
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
Oklahoma City, OK
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
Tualatin, OR
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
Tualatin, OR
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis
mi
from
Pittsburgh, PA
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis
mi
from
Pittsburgh, PA
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
Houston, TX
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
Houston, TX
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
Milwaulkee, WI
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
Milwaulkee, WI
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
mi
from
Wien,
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
mi
from
Wien,
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
VA Connecticut Healthcare System
mi
from
West Haven, CT
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
VA Connecticut Healthcare System
mi
from
West Haven, CT
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
Johns Hopkins Sibley Memorial Hospital
mi
from
Washington,
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
Johns Hopkins Sibley Memorial Hospital
mi
from
Washington,
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
University of Miami
mi
from
Miami, FL
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
University of Mississippi Medical Center
mi
from
Jackson, MS
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
Rutgers New Jersey Medical School
mi
from
Newark, NJ
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
Rutgers New Jersey Medical School
mi
from
Newark, NJ
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
North Shore University Hospital
mi
from
Manhasset, NY
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
New York University Lagone Medical Center
mi
from
NYC, NY
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
New York University Lagone Medical Center
mi
from
NYC, NY
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
Albert Einstein Medical Center
mi
from
Philadelphia, PA
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
Albert Einstein Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials